The European Federation of Pharmaceutical Industries and Associations (EFPIA) applauded the European Parliament’s decision Tuesday to adopt a recommendation permitting the Council of the European Union to adopt the Nagoya Protocol.
The decision on the protocol, which is designed to create greater legal certainty and transparency for both providers and users of genetic resources, will create new requirements for makers of seasonal flu vaccines, EFPIA says.
However, it also proposes to introduce benefits for companies that trade genetic resources in support of drug research and development. Those benefits may or may not be financial in nature.
The protocol will only be enforced once 50 states have ratified it.
Read the recommendation at www.fdanews.com/ext/resources/files/03/03-12-14-NagoyaRecommendation.pdf and the regulation at www.fdanews.com/ext/resources/files/03/03-12-14-NagoyaImplementation.pdf. — Lena Freund
Subscribe to Drug Industry Daily for complete coverage of the pharmaceutical industry. Click here for more information.